Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...eatment...
...w Recommendation from 2022 Guideline Rapid Reco...
...nts with T1cN1-2 or T2-4N0 (stage II or III)...
...ndidates...
...motherapy is the treatment of choice for...
...mor histology, grade, stage and estrogen, proge...
...oadjuvant systemic therapy should be offered to pa...
...ystemic therapy may be offered to reduce the exten...
...patients for whom a delay in surgery is preferabl...
Measuring Response
...asuring Respon...
...ts receiving neoadjuvant therapy should be moni...
...tissue-based biomarkers should not...
...ed as absence of invasive disease in breas...
Recommended Regimens for Patients with TNBC
...nded Regimens for Patients with TNBC...
...ts with TNBC who have clinically node p...
...ith cT1a or cT1bN0 TNBC should not routinely be o...
...may be offered as part of a neoadjuvant regim...
...insufficient evidence to recommend r...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...djuvant Treatment for Patients with HER2-...
...uvant chemotherapy can be used instead of...
...postmenopausal patients with HR+, HER2-negativ...
...nopausal patients with HR+, HER2-negative ea...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...ended Neoadjuvant Treatment for Patients with H...
...tients with node-positive or high-risk...
...1a N0 and T1b N0, HER2+ disease sho...